Search

Savara Inc

Fermé

SecteurSoins de santé

4.82 10.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.8

Max

4.88

Chiffres clés

By Trading Economics

Revenu

-2.9M

-40M

BPA

-0.16

Employés

70

EBITDA

-2.9M

-40M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+134.64% upside

Dividendes

By Acuity

Prochains Résultats

10 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-202M

972M

Ouverture précédente

-5.73

Clôture précédente

4.82

Savara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 nov. 2026, 21:02 UTC

Savara Inc. shares are advancing, showing a significant increase since Thursday's close, with unusually high trading volume despite earlier pulling back from a session high.

5 nov. 2026, 21:04 UTC

Correlated Moves

Savara Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF also experienced significant losses.

4 nov. 2026, 20:52 UTC

Savara Inc. shares fell sharply, remaining below their 20-day moving average amid unusually high market volume and significant fluctuations earlier in the session.

3 nov. 2026, 21:07 UTC

Savara Inc. shares are advancing, building on Monday's close, despite pulling back from an earlier session high amid overall modest market gains.

2 nov. 2026, 23:06 UTC

Savara Inc. shares advanced in after-market trading, gaining ground since Monday's close, following three consecutive sessions that finished lower.

30 oct. 2026, 20:08 UTC

Savara Inc. shares fell significantly, reflecting broader market weakness, and finished notably lower compared to Thursday's close.

29 oct. 2026, 20:06 UTC

Savara Inc. shares fell sharply as the broader market closed lower after an early peak.

28 oct. 2026, 20:02 UTC

Savara Inc. shares are advancing, diverging from a broader market downturn observed during Wednesday's session.

27 oct. 2026, 21:01 UTC

Savara Inc. shares declined modestly in after-market trading, remaining near the bottom of their range after a notable drop earlier in the session.

26 oct. 2026, 23:56 UTC

Savara Inc's shares advanced in after-market trading, reflecting a notable rise since Monday's close, though still below its 20-day moving average.

23 oct. 2026, 21:02 UTC

Savara Inc shares advanced in after-market trading, reaching a high shortly after the market closed before settling to a more modest gain.

22 oct. 2026, 20:07 UTC

News

Savara Inc's stock is declining after the company reiterated its Market Outperform rating and $10 price target, following new Molbreevi data presented at the CHEST conference.

21 oct. 2026, 23:16 UTC

Savara Inc is trading higher in after-market hours, gaining since Wednesday's close.

20 oct. 2026, 23:06 UTC

Savara Inc. shares advanced modestly in after-market hours, following a session that saw earlier peak gains before settling lower.

19 oct. 2026, 22:51 UTC

Savara Inc shares are moving higher in after-market trading, supported by an upward trend in the broader market, despite earlier session pullbacks.

16 oct. 2026, 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

15 oct. 2026, 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

14 oct. 2026, 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13 oct. 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 oct. 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 oct. 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 oct. 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 oct. 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 oct. 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 oct. 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 oct. 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30 sept. 2026, 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28 sept. 2026, 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25 sept. 2026, 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24 sept. 2026, 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

Comparaison

Variation de prix

Savara Inc prévision

Objectif de Prix

By TipRanks

134.64% hausse

Prévisions sur 12 Mois

Moyen 11.333 USD  134.64%

Haut 16 USD

Bas 9 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat